Bicycle sets terms for $65M IPO; Lilly's Cyramza wins fifth cancer approval
→ Oncology company Bicycle Therapeutics, which has put its faith in synthetic short peptides that it believes can deliver a payload better than antibodies, has broken out the terms of its IPO. The Cambridge, United Kingdom-based company plans to offer 4.3 million American Depositary Shares (ADSs) in the price range of $14 to $16 to raise $65 million, it said in a filing on Monday. Bicycle, which was founded in 2009 and has raised $147 million in cash already, plans to list under the symbol BCYC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.